Algiax Pharmaceuticals is a clinical-stage biotechnology company established in 2011. It is dedicated to the discovery and development of innovative products to treat diseases with a high unmet medical need.
Algiax’ lead candidate AP-325 is a small-molecule GABAA receptor modulator in clinical development as a therapy for neuropathic pain. A Phase IIa multi-center proof-of-concept study evaluating AP-325 in chronic neuropathic pain is currently running and expected to deliver first results by end of 2021.
GABAA is a major inhibitory neurotransmitter in the central nervous system. AP-325 is designed to treat a large group of neuropathic pain patients and does not penetrate the brain as such there are no sedative actions that limit their use.
Consequently, AP-325 as a non-opioid has a significantly lower potential for addiction or abuse and is truly unique because it is non-sedative, not centrally active and has a long-lasting efficacy.